Table of Content

Open Access iconOpen Access

ARTICLE

PSA density improves prediction of prostate cancer

Ashok Verma1, Jennifer St. Onge2, Kam Dhillon3, Anita Chorneyko3

1 Department of Diagnostic and Interventional Radiology, Regina Qu’Appelle Health Region, Regina, Saskatchewan, Canada
2 Research and Performance Support, Regina Qu’Appelle Health Region, Regina, Saskatchewan, Canada
3 Prostate Assessment Centre, Regina Qu’Appelle Health Region, Regina, Saskatchewan, Canada
Address correspondence to Dr. Jennifer St. Onge, Research and Performance Support, Regina Qu’Appelle Health Region, 2180-23rd Avenue, Regina, SK S4S 0A5 Canada

Canadian Journal of Urology 2014, 21(3), 7312-7321.

Abstract

Introduction: Prostate-specific antigen (PSA) and the digital rectal exam (DRE) have moderate sensitivity but low specificity for cancer diagnosis, potentially causing unnecessary treatment complications with prostate biopsy. Transrectal ultrasound (TRUS) to evaluate prostate size and calculate PSA density can improve the specificity of PSA in predicting cancer. We evaluated the sensitivity and specificity of different pre-biopsy tests to detect prostate cancer.
Materials and methods: Pre-biopsy data were collected from 521 men referred for biopsy from January–December 2011 and cancer aggressiveness data from 96 men who had radical prostatectomy. Model predictors included total PSA, DRE, the ratio of free to total PSA (PSAf/t), and PSA density. We used logistic regression and ROC curve analyses to compare the accuracy of different models to predict positive biopsy.
Results: The area under the curve (AUC) for model A (PSA total, DRE, PSAf/t) was moderate, but significant (AUC = 0.59, p < 0.05); only PSAf/t was a significant independent predictor of positive biopsy (OR = 0.002, p < 0.05). In model B (PSAf/t and PSA density; AUC = 0.66, p < 0.05), PSA density was the only strong predictor (OR = 1067.93, p < 0.05). Both models had comparable sensitivity (74% versus 72%) but model B had greater specificity (44% versus 61%). PSA density was also a significant predictor of different indices of aggressive cancer.
Conclusions: PSA density has discriminative predictive power for prostate cancer. It had similar sensitivity, but greater specificity compared to using PSA total, DRE and PSAf/t. These results support the value of using PSA density to improve prediction of prostate cancer and reduce unnecessary biopsies.

Keywords

prostate-specific antigen, prostate volume, PSA density, aggressive cancer

Cite This Article

APA Style
Verma, A., Onge, J.S., Dhillon, K., Chorneyko, A. (2014). PSA density improves prediction of prostate cancer. Canadian Journal of Urology, 21(3), 7312–7321.
Vancouver Style
Verma A, Onge JS, Dhillon K, Chorneyko A. PSA density improves prediction of prostate cancer. Can J Urology. 2014;21(3):7312–7321.
IEEE Style
A. Verma, J.S. Onge, K. Dhillon, and A. Chorneyko, “PSA density improves prediction of prostate cancer,” Can. J. Urology, vol. 21, no. 3, pp. 7312–7321, 2014.



cc Copyright © 2014 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 139

    View

  • 128

    Download

  • 0

    Like

Share Link